BioWorld

Dec. 27, 2005

Experimental Study Supports Population Selection In Viruses

Alexza Files For $86.25M IPO To Carry Aerosol Drug Work

Progenics, Wyeth Sign MNTX Agreement Worth Up To $416M

Progenics Pharmaceuticals Inc. picked up a worldwide partner for methylnaltrexone (MNTX), its investigational treatment of opioid-induced side effects, signing a deal with Wyeth Pharmaceuticals for up to $416 million. (BioWorld Today) Read More

EntreMed Acquiring Cancer Company Miikana For $21M

Today's news in brief

BioWorld

BioWorld briefs for March 30, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026

BioWorld

Dec. 27, 2005

Experimental Study Supports Population Selection In Viruses

Alexza Files For $86.25M IPO To Carry Aerosol Drug Work

Holiday notice

Appointments And Advancements

Other News To Note

Progenics, Wyeth Sign MNTX Agreement Worth Up To $416M

EntreMed Acquiring Cancer Company Miikana For $21M

Today's news in brief

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

Small-molecule TREM2 agonist advances to treat Alzheimer’s

With improved technologies, biomarkers, failed drugs may come into their own

News in brief